• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Ocular Theraputix

Quote




anonymous said:
Anyone know about the company? Good product?
Click to expand...

Product not yet approved, company is doing a contract sales force for at least the first year. Interviewing process is ridiculous & apparently they have no idea dripless is taking over the market bc they think hospitals & ASCs are going to pay $400 for this?!
 








Or it's never coming out...FDA issued CRL yesterday due to manufacturing issues. Even if it does do they really think there is a market for this anymore? Apparently this pharma blow hards have 0.0 connections to surgical reps bc they would have told them the dropless ship has sailed. Inserting a punctual for slow release drug would have been a step backwards and a more expensive one at that!?!

What will the arrogant midwestern manager JB do now that he is laid off again?! He was such a tool in the interviewing process and obviously had a huge chip on his shoulder for never being able to make it from Alcon pharma to surgical.
 








Top Bottom
Back
Quote